Digi International Bolsters Digi Connect EZ Family of Device Servers with Launch of 8/16/32 Port Options
6.4.2023 15:00:00 EEST | Business Wire | Press release
Digi International, (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) connectivity products and services, today announced the launch of Digi Connect® EZ 8/16/32. This solution represents the latest in Digi’s line of next-generation device servers providing secure, scalable connectivity for business, commercial, and industrial automation applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005005/en/
Digi Connect EZ 8/16/32 comes with a one-year subscription to Digi’s LifeCycle Assurance Program, providing customers with access to Digi Remote Manager Premier edition and 24/7 expert technical support. (Photo: Business Wire)
The product expansion underscores Digi’s commitment to supporting critical industries spanning utilities, energy, aerospace, government, commercial, logistics and factory automation with intelligent end-to-end serial connectivity solutions. Combining state-of-the-art hardware with the robust Digi Accelerated Linux (DAL) operating system, the Digi Connect EZ 8/16/32 line offers a range of industry-leading features. These include cellular support and the unparalleled central management capabilities of Digi Remote Manager® (Digi RM). This platform enables in-depth, 360-degree visibility to configure, deploy, and manage remote assets securely.
Also included with Digi Connect EZ 8/16/32 is a one-year subscription to Digi’s LifeCycle Assurance Program, providing customers with access to Digi Remote Manager Premier edition and 24/7 expert technical support.
“We are excited to expand the Digi Connect EZ family, providing enhanced solutions and devices that enable our customers to conveniently and securely scale their operations today, while preemptively addressing the IIoT challenges of tomorrow,” said Brian Kirkendall, General Manager and Vice President of Infrastructure Management at Digi. “The incorporation and availability of our wider product features such as cellular support, central management with Digi RM, and round-the-clock expert assistance underscore Digi’s ongoing commitment to supporting customers throughout the entire product lifecycle.”
Hardware-enabled and software-defined, the Connect EZ family of products delivers a scalable solution that supports multiple serial interfaces in both industrial and non-industrial environments. Digi Connect EZ prevents data loss, providing state of the art communication technology to meet the needs of machine-to-machine serial communication customers all over the world. Additionally, the Connect EZ family offers an updated hardware platform that ensures longevity, manageability, and deployment flexibility. To manage critical serially connected equipment at scale, the Connect EZ family adheres to the following key attributes:
- Scalability — Simple click-to-connect deployment using Digi Navigator, with quick configuration providing easy integration for a wide range of use cases. Digi Connect EZ is truly easy to deploy and manage at scale throughout the product lifecycle with robust security, management and device health capabilities.
- Reliability — Built on top of the Digi TrustFence® design architecture and DAL operating system, Digi Connect EZ is designed for deployment in industrial environments to offer a secure, stable, and resilient platform for mission-critical connectivity, including LTE and Wi-Fi.
- Capability — Supports a wide range of industry standard and device-specific protocols using serial tunneling, and TCP/UDP connections or Digi’s patented RealPort® COM port redirector for remote native COM port access. Additionally, the built-in Python environment enables application development and customization at the device level, including event-based programmability, data conversion and full control of device connections.
“No matter the industry, no matter the challenge — from industrial automation to large scale manufacturing to secure communication of critical data — we’ve got our customers covered,” Kirkendall continued. “With the Connect EZ 8/16/32 expansion, we’re delivering the scalable and secure end-to-end connectivity solution our customers not only need, but that they deserve.”
Availability
Digi Connect EZ® 8/16/32 devices are available for immediate purchase now.
Explore the solutions here:
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. We help our customers create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, we’ve helped our customers connect over 100 million things and growing. For more information, visit Digi's website at www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005005/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom